COLLABORATION AND LICENSE AGREEMENT by and between CYTOMX THERAPEUTICS, inc. and REGENERON PHARMACEUTICALS, INC. Dated as of November 16, 2022Collaboration and License Agreement • March 27th, 2023 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (“Agreement”) is entered into as of November 16, 2022 (the “Effective Date”) by and between CytomX Therapeutics, Inc., organized and existing under the laws of Delaware with its principal place of business at 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080, U.S.A. (“CytomX”) and Regeneron Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of New York with its principal place of business at 777 Old Saw Mill River Road, Tarrytown NY 10591 (“Regeneron”). CytomX and Regeneron are each hereafter referred to individually as a “Party” and together as the “Parties.”
COLLABORATION AND LICENSE AGREEMENT by and between CYTOMX THERAPEUTICS, inc. and MODERNATX, INC. Dated as of December 30, 2022Collaboration and License Agreement • March 27th, 2023 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • New York
This Collaboration and License Agreement (“Agreement”) is entered into as of December 30, 2022 (the “Effective Date”) by and between CytomX Therapeutics, Inc., organized and existing under the laws of Delaware with its principal place of business at 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080, U.S.A. (“CytomX”) and ModernaTX, Inc., a corporation organized and existing under the laws of Delaware with its principal place of business at 200 Technology Square, Cambridge, Massachusetts 02139 (“Moderna”). CytomX and Moderna are each hereafter referred to individually as a “Party” and together as the “Parties”.
